MedTrace Logo

Blood Lipid-lowering Effect of Brown Alga Ecklonia Cava

NCT02091024 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-03-19

No results posted yet for this study

Summary

The investigators performed a 12-week, randomized, double-blind, placebo-controlled human trial to evaluate the efficacy and safety of Ecklonia cava extract on hyperlipidemia.

Conditions

Interventions

DIETARY_SUPPLEMENT

ECE (Ecklonia cava extract)

ECE 200mg, twice a day

DIETARY_SUPPLEMENT

Placebo

Placebo 200mg, twice a day

Sponsors & Collaborators

  • Chonbuk National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02091024 on ClinicalTrials.gov